Tin tức & Cập nhật
Xem bài viết Dược
Xem

Mirabegron a potentially safer alternative to solifenacin for paediatric OAB
In the treatment of overactive bladder (OAB) in children, mirabegron demonstrates efficacy similar to that of solifenacin but has a better safety profile, according to a meta-analysis presented at the annual EAU Congress.
Mirabegron a potentially safer alternative to solifenacin for paediatric OAB
28 Mar 2026
Digital intervention plus phentermine-topiramate cuts weight, CVD risk in adults with obesity
Combination treatment with phentermine-topiramate extended release (ER) and a digitally enhanced lifestyle intervention (DELI) results in a significant and sustained weight reduction, as well as a decrease in cardiovascular disease (CVD) risk, in adults with obesity, reports a study.
Digital intervention plus phentermine-topiramate cuts weight, CVD risk in adults with obesity
28 Mar 2026
Avacincaptad pegol slows geographic atrophy progression
Patients with noncentre point-involving geographic atrophy (GA) who receive avacincaptad pegol (ACP) 2 mg every month (EM) or every other month (EOM) show a persistent decrease in GA growth over 2 years relative to sham therapy, with no new safety signals, according to the GATHER2 study.
Avacincaptad pegol slows geographic atrophy progression
27 Mar 2026
2-year data support nerve-sparing technique in prostate cancer surgery
An updated 24-month analysis of the NeuroSAFE PROOF study continues to support robot-assisted radical prostatectomy (RARP) guided by the nerve-sparing NeuroSAFE technique in men with prostate cancer.
2-year data support nerve-sparing technique in prostate cancer surgery
27 Mar 2026
Pre-TURBT mitomycin-C improves RFS in NMIBC
In the updated 5-year analysis of a randomized phase II trial, administering two doses of intravesical mitomycin-C (MMC) immediately before transurethral resection of bladder tumour (TURBT) improves recurrence-free survival (RFS) in individuals with non-muscle invasive bladder cancer (NMIBC).




